AEVIS VICTORIA SA – Revenues from operating divisions are increasing, with positive forecasts for the current year. Growth for 1Q2024 is 7.2%.
|
AEVIS VICTORIA SA / Key word(s): Miscellaneous Ad hoc announcement pursuant to Art. 53 LR Fribourg, 2 May 2024 AEVIS VICTORIA SA (AEVS.SW) – Revenues from operating divisions are increasing, with positive forecasts for the current year. Growth for 1Q2024 is 7.2%. AEVIS VICTORIA SA (AEVIS) reported consolidated revenues for the first quarter of 2024 of CHF 281.9 million (1Q2023: CHF 263.0 million), an increase of 7.2%. AEVIS's operating divisions, Swiss Medical Network and MRH Switzerland AG, performed very well in the first quarter of 2024, with organic revenue growth of 6.2%. Growth continues in the second quarter and the Group is actively working to reduce operating costs. Swiss Medical Network SA achieved revenues of CHF 213.0 million (1Q2023: CHF 203.6 million), up by 4.6%. All Swiss Medical Network hospitals have contracts with all Swiss insurance companies. On 1 January 2024, Swiss Medical Network launched the first integrated care region in the Jura Arc with the exclusive insurance product «Viva», developed in partnership with Visana. With «Viva», Visana and Swiss Medical Network are leading a radical transformation of the healthcare system in Switzerland. Other regions will follow in 2025 and 2026. Fabrice Zumbrunnen, CEO of AEVIS, also took over the position as Delegate of the Board of Directors of Swiss Medical Network on 1 May 2024, replacing Antoine Hubert, who remains on the Board of Directors. Since June 2023, Fabrice Zumbrunnen has been actively involved in the implementation of «Viva» alongside the teams of Réseau de l’Arc. MRH Switzerland AG (formerly Victoria-Jungfrau AG) continued to grow with consolidated revenues up 15.0% to CHF 64.7 million (1Q2023: CHF 56.3 million), driven by organic growth of 13.8%, particularly in Davos, Interlaken, and Zermatt. For further information: AEVIS VICTORIA SA - Investing for a better life End of Inside Information |
1893677 02-May-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.